Selegiline

Selegiline (Deprenyl) is a potent, selective and irreversible inhibitor of MAO-B, with an IC₅₀ of 51 nM. Selegiline exhibits 450-flod selectivity for MAO-B over MAO-A (IC₅₀=23 μM). Selegiline can be used for the research of Parkinson's disease, Alzheimer's disease and major depressive disorder^[1][2][3]. In Vitro: Selegiline (1 nM-1 μM) inhibits recombinant human MAO-B in a concentration-dependent manner^[1].
Selegiline (10 mM) increases the efflux of norepinephrine (NE), dopamine (DA) and serotonin (5-HT) from the rat hypothalamus in vitro. Selegiline inhibits the efflux of dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA) in a dose-dependent manner^[3]. In Vivo: Selegiline (1 mg/kg; i.p. daily for 24 days) reduces Cocaine self-administration of mice and does not affect Cocaine-caused body weight loss. Selegiline reduces 3,4-dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA) concentrations in frontal cortex^[4].